PMA device
OneTouch Vibe Plus System
Animas Corp. · Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC, Class III) · First FDA decision Dec 16, 2016, newest Dec 16, 2016Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "OneTouch Vibe Plus"
MAUDE reports
0
Brand "OneTouch Vibe Plus", since 2015
PubMed studies
0
Mentioning "OneTouch Vibe Plus"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OneTouch Vibe Plus System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- OneTouch Vibe Plus SystemPMA supplement
P130007-S016 · Decided Dec 16, 2016 · 193 days after receipt · Panel Track
Device type: Pump, infusion, insulin, to be used with invasive glucose sensor (OYC) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Insulin Infusion PumpNational analysisReview closedCAG-00041NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "OneTouch Vibe Plus", any status and sponsor, newest update first.
No registered device study names "OneTouch Vibe Plus".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OneTouch Vibe Plus", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OYC
806,010 reports: 698,599 malfunction, 105,709 injury, 1,552 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1034-2015 · Started Sep 6, 2011 · Posted by FDA Jan 30, 2015
Reason given: Calibration factors in the pump overwritten during a programming step. The force sensor could send a lower signal value to the pump processor, with loss of prime warnings, occlusion alarms and the pump unable to detect a cartridge during the prime sequence. Field action initiated 8/29/2011.
Cause as FDA categorized it: Software design (manufacturing process) · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Published research
The most relevant PubMed records for "OneTouch Vibe Plus"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OYC.
- t:slim G4 Insulin Pump with Dexcom G4 Platinum CGMTandem Diabetes Care, Inc. · PMA 2017
- t:slim X2 Insulin Pump with Dexcom G5 Mobile CGMTandem Diabetes Care, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.